Li Y - Search Results

1

Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.

Qu CF, Song EY, Li Y, Rizvi SM, Raja C, Smith R, Morgenstern A, Apostolidis C, Allen BJ. Qu CF, et al. Among authors: li y. Clin Exp Metastasis. 2005;22(7):575-86. doi: 10.1007/s10585-005-5788-9. Epub 2006 Feb 11. Clin Exp Metastasis. 2005. PMID: 16475028

2

In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells.

Li Y, Wang J, Rizvi SM, Jager MJ, Conway RM, Billson FA, Allen BJ, Madigan MC. Li Y, et al. Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4365-71. doi: 10.1167/iovs.05-0559. Invest Ophthalmol Vis Sci. 2005. PMID: 16303921

3

Intralesional targeted alpha therapy for metastatic melanoma.

Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Graham P, Thompson JF, Reisfeld RA, Kearsley J. Allen BJ, et al. Among authors: li y. Cancer Biol Ther. 2005 Dec;4(12):1318-24. doi: 10.4161/cbt.4.12.2251. Epub 2005 Dec 18. Cancer Biol Ther. 2005. PMID: 16322682 Free article. Clinical Trial.

4

MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer.

Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ, Li Y. Cozzi PJ, et al. Among authors: li y. Clin Exp Metastasis. 2005;22(7):565-73. doi: 10.1007/s10585-005-5376-z. Epub 2006 Feb 11. Clin Exp Metastasis. 2005. PMID: 16475027

5

Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model.

Abbas Rizvi SM, Li Y, Song EY, Qu CF, Raja C, Morgenstern A, Apostolidis C, Allen BJ. Abbas Rizvi SM, et al. Among authors: li y. Cancer Biol Ther. 2006 Apr;5(4):386-93. doi: 10.4161/cbt.5.4.2478. Epub 2006 Apr 4. Cancer Biol Ther. 2006. PMID: 16575210 Free article.

6

Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.

Cozzi PJ, Wang J, Delprado W, Madigan MC, Fairy S, Russell PJ, Li Y. Cozzi PJ, et al. Among authors: li y. Hum Pathol. 2006 Nov;37(11):1442-51. doi: 10.1016/j.humpath.2006.05.002. Epub 2006 Jul 26. Hum Pathol. 2006. PMID: 16949925

7

Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates.

Wang J, Abbas Rizvi SM, Madigan MC, Cozzi PJ, Power CA, Qu CF, Morgenstern A, Apostolidis C, Russell PJ, Allen BJ, Li Y. Wang J, et al. Among authors: li y. Prostate. 2006 Dec 1;66(16):1753-67. doi: 10.1002/pros.20502. Prostate. 2006. PMID: 16955401

8

The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy.

Song EY, Rizvi SM, Qu CF, Raja C, Yuen J, Li Y, Morgenstern A, Apostolidis C, Allen BJ. Song EY, et al. Among authors: li y. Phys Med Biol. 2008 Jan 21;53(2):319-28. doi: 10.1088/0031-9155/53/2/001. Epub 2007 Dec 28. Phys Med Biol. 2008. PMID: 18184988

9

Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates.

Li Y, Song E, Abbas Rizvi SM, Power CA, Beretov J, Raja C, Cozzi PJ, Morgenstern A, Apostolidis C, Allen BJ, Russell PJ. Li Y, et al. Clin Cancer Res. 2009 Feb 1;15(3):865-75. doi: 10.1158/1078-0432.CCR-08-1203. Clin Cancer Res. 2009. PMID: 19188157

10

Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression.

Chen H, Wang L, Beretov J, Hao J, Xiao W, Li Y. Chen H, et al. Among authors: li y. Clin Exp Metastasis. 2010 Dec;27(8):557-69. doi: 10.1007/s10585-010-9345-9. Epub 2010 Jul 24. Clin Exp Metastasis. 2010. PMID: 20658178

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

236,656 results

Search Page

Filters